Westfuller Advisors LLC Grows Stake in Johnson & Johnson $JNJ

Westfuller Advisors LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 107.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 7,440 shares of the company’s stock after purchasing an additional 3,860 shares during the quarter. Westfuller Advisors LLC’s holdings in Johnson & Johnson were worth $1,379,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Clark Asset Management LLC raised its stake in shares of Johnson & Johnson by 51.6% in the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after purchasing an additional 3,025 shares during the last quarter. Treasurer of the State of North Carolina boosted its position in Johnson & Johnson by 8.3% in the second quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock valued at $188,638,000 after buying an additional 94,957 shares during the last quarter. Talbot Financial LLC increased its holdings in Johnson & Johnson by 4.6% in the 3rd quarter. Talbot Financial LLC now owns 138,424 shares of the company’s stock worth $25,667,000 after buying an additional 6,143 shares during the period. Liberty One Investment Management LLC raised its position in Johnson & Johnson by 83.9% during the 3rd quarter. Liberty One Investment Management LLC now owns 366,813 shares of the company’s stock worth $68,040,000 after buying an additional 167,353 shares during the last quarter. Finally, Winnow Wealth LLC acquired a new stake in Johnson & Johnson during the 2nd quarter valued at approximately $295,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

JNJ has been the subject of several recent research reports. Bank of America raised their target price on shares of Johnson & Johnson from $220.00 to $221.00 and gave the stock a “neutral” rating in a report on Thursday. Wolfe Research lifted their price objective on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research note on Monday, January 5th. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a report on Thursday. Freedom Capital lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. Finally, Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Sunday. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $226.18.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $220.29 on Monday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The stock has a market capitalization of $530.74 billion, a P/E ratio of 19.94, a P/E/G ratio of 2.14 and a beta of 0.34. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $222.17. The company’s fifty day moving average price is $208.35 and its 200 day moving average price is $189.39.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, hitting analysts’ consensus estimates of $2.46. The business had revenue of $24.56 billion during the quarter, compared to analysts’ expectations of $24.14 billion. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. The company’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.